Anti-CD20 therapy and autoimmune disease: Therapeutic opportunities and evolving insights

被引：20

作者：

Silverman, Gregg J. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, Rheumat Dis Core Ctr, La Jolla, CA 92093 USA

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2007年 / 12卷

关键词：

drug; immune system; autoimmunity; SLE; systemic lupus erythromatosus; RA; rheumatoid arthritis; therapy; CD-20; tolerance; apoptosis; host immunity; review; B-CELL DEPLETION; FC-GAMMA-RIIIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; ALPHA-4-BETA-1; INTEGRIN; COMPLEMENT ACTIVATION; DOWN-REGULATION; PLASMA-CELLS; RITUXIMAB;

D O I：

10.2741/2222

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Based on the successful clinical experience with the anti-CD20 antibody, rituximab, for the treatment of B-cell non-Hodgkins lymphoma, there is a rapidly growing literature on the treatment of patients with autoimmune diseases with this therapeutic agent. However, the pathogenetic mechanisms responsible for these diseases may differ greatly from those in B cell malignancies. Herein, I provide an overview on recently published clinical experience, and discuss immunobiologic perspectives that are most relevant to understanding the special opportunities and challenges posed by these diseases. Of special importance, there is emerging evidence that the same inherited genetic variations and acquired immunodefects that underlie autoimmune disease pathogenesis may in some patients also interfere with the efficacy of anti-CD20 antibody-based therapy.

引用

页码：2194 / 2206

页数：13

共 79 条

[1] Down-regulation of CD20 on B cells upon CD40 activation [J].

Anolik, J ;

Looney, RJ ;

Bottaro, A ;

Sanz, I ;

Young, F .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (09) :2398-2409

[2] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Sanz, I ;

Rosenblatt, J ;

Looney, RJ .

ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459

[3]

ANOLIK JH, 2003, ARTHRITIS RHEUM S9, V48

[4] CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow [J].

Avigdor, A ;

Goichberg, P ;

Shivtiel, S ;

Dar, A ;

Peled, A ;

Samira, S ;

Kollet, O ;

Hershkoviz, R ;

Alon, R ;

Hardan, I ;

Ben-Hur, H ;

Naor, D ;

Nagler, A ;

Lapidot, T .

BLOOD, 2004, 103 (08) :2981-2989

[5]

Baumgarth N, 1999, P NATL ACAD SCI USA, V96, P2250, DOI 10.1073/pnas.96.5.2250

[6] Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura [J].

Bell, WR .

SEMINARS IN HEMATOLOGY, 2000, 37 (01) :22-25

[7] C1q, autoimmunity and apoptosis [J].

Botto, M ;

Walport, MJ .

IMMUNOBIOLOGY, 2002, 205 (4-5) :395-406

[8] HUMAN-COMPLEMENT ACTIVATION BY SELF-ASSOCIATED IGG RHEUMATOID FACTORS [J].

BROWN, PB ;

NARDELLA, FA ;

MANNIK, M .

ARTHRITIS AND RHEUMATISM, 1982, 25 (09) :1101-1107

[9] Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1-and CD106 (VCAM-1)-dependent mechanism [J].

Burger, JA ;

Zvaifler, NJ ;

Tsukada, N ;

Firestein, GS ;

Kipps, TJ .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :305-315

[10] Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis [J].

Cambridge, G ;

Leandro, MJ ;

Edwards, JCW ;

Ehrenstein, MR ;

Salden, M ;

Bodman-Smith, M ;

Webster, ADB .

ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2146-2154

← 1 2 3 4 5 6 7 8 →